Clinical Trials
2 trialsNCT04879329 2026-04-21
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Seagen Inc.
Phase 2 Recruiting
NCT05911295 2026-04-20
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen Inc.
Phase 3 Active not recruiting